Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A14399 | 29427494 | Liver Int | Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough. | 2018 | Details |
| A14400 | 29427492 | Liver Int | Future therapy for non-alcoholic fatty liver disease. | 2018 | Details |
| A14401 | 29427488 | Liver Int | Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. | 2018 | Details |
| A14408 | 29424123 | J Gastroenterol Hepatol | Mouse models of non-alcoholic steatohepatitis: A reflection on recent literature. | 2018 | Details |
| A14409 | 29421523 | Transl Res | Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet. | 2018 | Details |
| A14411 | 29420066 | Am J Physiol Gastrointest Liver Physiol | CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. | 2018 | Details |
| A14417 | 29416063 | Nat Commun | AhR and SHP regulate phosphatidylcholine and S-adenosylmethionine levels in the one-carbon cycle. | 2018 | Details |
| A14419 | 29414910 | Molecules | Hepatoprotective Effects of a Functional Formula of Three Chinese Medicinal Herbs: Experimental Evidence and Network Pharmacology-Based Identification of Mechanism of Action and Potential Bioactive Components. | 2018 | Details |
| A14422 | 29414249 | Annu Rev Pathol | Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A14424 | 29413959 | Redox Biol | Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. | 2018 | Details |
| A14427 | 29411270 | Adv Ther | Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. | 2018 | Details |
| A14431 | 29409822 | Metabolism | Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. | 2018 | Details |
| A14438 | 29406832 | Can J Physiol Pharmacol | Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease. | 2018 | Details |
| A14440 | 29406435 | Eur J Gastroenterol Hepatol | Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. | 2018 | Details |
| A14442 | 29404772 | Eur Radiol | Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis. | 2018 | Details |
| A14443 | 29404527 | Hepatol Commun | Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. | 2017 | Details |
| A14444 | 29404514 | Hepatol Commun | Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. | 2017 | Details |
| A14445 | 29404513 | Hepatol Commun | Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease. | 2017 | Details |
| A14446 | 29404512 | Hepatol Commun | Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. | 2017 | Details |
| A14448 | 29404500 | Hepatol Commun | Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. | 2017 | Details |
| A14449 | 29404494 | Hepatol Commun | Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. | 2017 | Details |
| A14451 | 29404470 | Hepatol Commun | Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. | 2017 | Details |
| A14452 | 29404465 | Hepatol Commun | Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation. | 2017 | Details |
| A14453 | 29404440 | Hepatol Commun | Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice. | 2017 | Details |
| A14454 | 29404433 | Hepatol Commun | Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. | 2017 | Details |
| A14455 | 29402900 | Sci Rep | Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. | 2018 | Details |
| A14464 | 29399288 | World J Hepatol | Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. | 2018 | Details |
| A14466 | 29399276 | World J Hepatol | Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. | 2018 | Details |
| A14467 | 29399273 | World J Hepatol | Role of inflammatory response in liver diseases: Therapeutic strategies. | 2018 | Details |
| A14472 | 29398327 | J Diabetes Complications | Differing clinical phenotype for higher alanine-aminotransferase (ALT) compared with high-risk NAFLD fibrosis score in type 2 diabetes mellitus. | 2017 | Details |
| A14481 | 29391222 | Adv Drug Deliv Rev | MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. | 2018 | Details |
| A14493 | 29384795 | Eur J Gastroenterol Hepatol | Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina. | 2018 | Details |
| A14498 | 29380318 | Methods Mol Biol | Assessment of Fatty Liver in Models of Disease Programming. | 2018 | Details |
| A14503 | 29378307 | Clin Gastroenterol Hepatol | Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. | 2018 | Details |
| A14506 | 29377462 | Liver Int | Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. | 2018 | Details |
| A14512 | 29375205 | World J Gastroenterol | INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. | 2018 | Details |
| A14513 | 29375204 | World J Gastroenterol | Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. | 2018 | Details |
| A14517 | 29372507 | Hepatol Int | Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease. | 2018 | Details |
| A14519 | 29371918 | Oncotarget | Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL/6J mice by inhibiting de-novo lipogenesis. | 2017 | Details |
| A14523 | 29368124 | Dig Dis Sci | Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A14528 | 29367468 | JCI Insight | DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis. | 2018 | Details |
| A14529 | 29367207 | Gut | Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. | 2018 | Details |
| A14551 | 29358469 | Diabetes Care | Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. | 2018 | Details |
| A14552 | 29357809 | Cardiovasc Hematol Agents Med Chem | Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease. | 2018 | Details |
| A14557 | 29355950 | J Pharm Pharmacol | Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats. | 2018 | Details |
| A14558 | 29355688 | Toxicol Lett | Metabolomics profiling of steatosis progression in HepaRG® cells using sodium valproate. | 2018 | Details |
| A14570 | 29349944 | J Korean Med Sci | Investigation of Clinical and Pathological Relationships between Adult- and Pediatric-type NASH in Korean Children. | 2018 | Details |
| A14576 | 29344336 | Ther Adv Endocrinol Metab | Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. | 2017 | Details |
| A14579 | 29342182 | PLoS One | Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. | 2018 | Details |
| A14585 | 29338271 | Rev Esp Enferm Dig | Analytical, anthropometric and dietary factors associated with the development of fibrosis in patients with nonalcoholic fatty liver disease. | 2018 | Details |
| A14590 | 29335916 | Sleep Breath | Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. | 2018 | Details |
| A14592 | 29335425 | Sci Rep | SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease. | 2018 | Details |
| A14596 | 29333610 | Aliment Pharmacol Ther | Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. | 2018 | Details |
| A14599 | 29330836 | Hepatol Int | Pathogenesis of non-alcoholic fatty liver disease mediated by YAP. | 2018 | Details |
| A14600 | 29330220 | Drug Metab Dispos | Regulation of Drug Metabolism by the Interplay of Inflammatory Signaling, Steatosis, and Xeno-Sensing Receptors in HepaRG Cells. | 2018 | Details |
| A14603 | 29328026 | Georgian Med News | CLINICAL EFFICACY OF S-ADENOSYLMETHIONINE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS AND CHRONIC KIDNEY DISEASE I-II STAGE. | 2017 | Details |
| A14604 | 29327118 | Sleep Breath | Effect of CPAP therapy on liver disease in patients with OSA: a review. | 2018 | Details |
| A14607 | 29326427 | Lab Invest | Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats. | 2018 | Details |
| A14610 | 29325281 | Zhonghua Gan Zang Bing Za Zhi | [Value of hydrogen proton magnetic resonance spectroscopy in the determination of liver triglyceride in patients with fatty liver disease and its influencing factors]. | 2017 | Details |
| A14624 | 29318450 | Hepatol Int | The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients. | 2018 | Details |
| A14627 | 29316577 | Z Gastroenterol | [Combination of NAFLD Fibrosis Score and liver stiffness measurement for identification of moderate fibrosis stages (II & III) in non-alcoholic fatty liver disease]. | 2018 | Details |
| A14630 | 29316028 | Hepatol Res | Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. | 2018 | Details |
| A14641 | 29311502 | Exp Anim | A novel hamster nonalcoholic steatohepatitis model induced by a high-fat and high-cholesterol diet. | 2018 | Details |
| A14651 | 29308929 | Biomarkers | New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fatty liver disease. | 2018 | Details |
| A14653 | 29307986 | World J Gastroenterol | Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. | 2017 | Details |
| A14671 | 29294263 | Postepy Biochem | [NAFLD pathogenesis in the light of recent research]. | 2019 | Details |
| A14674 | 29291351 | Nat Med | The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. | 2018 | Details |
| A14682 | 31938096 | Int J Clin Exp Pathol | A nonalcoholic fatty liver disease cirrhosis model in gerbil: the dynamic relationship between hepatic lipid metabolism and cirrhosis. | 2018 | Details |
| A14684 | 31149239 | Acta Endocrinol (Buchar) | VITAMIN D DEFICIENCY, A NONINVASIVE MARKER OF STEATOHEPATITIS IN PATIENTS WITH OBESITY AND BIOPSY PROVEN NONALCOHOLIC FATTY LIVER DISEASE. | 2022 | Details |
| A14688 | 29288403 | Heart Vessels | The impact of non-alcoholic fatty liver disease fibrosis score on cardiac prognosis in patients with chronic heart failure. | 2017 | Details |
| A14691 | 29287776 | Biochim Biophys Acta Mol Basis Dis | Activin-A causes Hepatic stellate cell activation via the induction of TNFα and TGFβ in Kupffer cells. | 2017 | Details |
| A14693 | 29287676 | Clin Nutr | Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition. | 2017 | Details |
| A14695 | 29286303 | Nutrients | Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD). | 2017 | Details |
| A14697 | 29286155 | Mol Med Rep | Mesenchymal stem cells reverse high‑fat diet‑induced non‑alcoholic fatty liver disease through suppression of CD4+ T lymphocytes in mice. | 2017 | Details |
| A14699 | 29285942 | Orv Hetil | [Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases]. | 2017 | Details |
| A14701 | 29281143 | Br J Pharmacol | The soluble guanylate cyclase stimulator IW-1973 prevents inflammation and fibrosis in experimental non-alcoholic steatohepatitis. | 2018 | Details |
| A14703 | 29280921 | Eur J Gastroenterol Hepatol | Impact of steatosis and inflammation definitions on the performance of NASH tests. | 2018 | Details |
| A14704 | 29280273 | J Intern Med | Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. | 2017 | Details |
| A14707 | 29279175 | Eur J Radiol | MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease. | 2017 | Details |
| A14708 | 29278765 | Magn Reson Imaging | Gd-EOB-DTPA-enhanced T1ρ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits. | 2017 | Details |
| A14711 | 29276754 | Cell Mol Gastroenterol Hepatol | Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model. | 2017 | Details |
| A14712 | 29276410 | Clin Epidemiol | Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. | 2017 | Details |
| A14715 | 29274406 | J Hepatol | Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. | 2017 | Details |
| A14717 | 29274190 | Hepatol Res | Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein. | 2018 | Details |
| A14718 | 29273476 | J Hepatol | Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice. | 2017 | Details |
| A14722 | 29271504 | Aliment Pharmacol Ther | Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. | 2017 | Details |
| A14726 | 29270247 | Oxid Med Cell Longev | Deficiency of the Purinergic Receptor 2X7 Attenuates Nonalcoholic Steatohepatitis Induced by High-Fat Diet: Possible Role of the NLRP3 Inflammasome. | 2017 | Details |
| A14728 | 29269684 | Intern Med | The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus. | 2017 | Details |
| A14731 | 29268106 | J Nutr Biochem | Food components with antifibrotic activity and implications in prevention of liver disease. | 2017 | Details |
| A14734 | 29266667 | Aging Cell | Plasticity of lifelong calorie-restricted C57BL/6J mice in adapting to a medium-fat diet intervention at old age. | 2017 | Details |
| A14735 | 29266399 | Hepatology | Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein. | 2018 | Details |
| A14743 | 29262266 | Appl Physiol Nutr Metab | Effect of a short-term physical activity intervention on liver fat content in obese children. | 2017 | Details |
| A14749 | 29256057 | Clin Rev Allergy Immunol | The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. | 2018 | Details |
| A14750 | 29255745 | GE Port J Gastroenterol | Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease. | 2016 | Details |
| A14764 | 29249184 | Hum Exp Toxicol | Caffeine affects HFD-induced hepatic steatosis by multifactorial intervention. | 2017 | Details |
| A14766 | 29249016 | Hum Cell | Therapeutic activity of plant-derived alkaloid conophylline on metabolic syndrome and neurodegenerative disease models. | 2017 | Details |
| A14767 | 29248461 | Am J Pathol | Knockout of l-Histidine Decarboxylase Prevents Cholangiocyte Damage and Hepatic Fibrosis in Mice Subjected to High-Fat Diet Feeding via Disrupted Histamine/Leptin Signaling. | 2017 | Details |
| A14768 | 29247950 | Biomed Pharmacother | Baicalin attenuates diet induced nonalcoholic steatohepatitis by inhibiting inflammation and oxidative stress via suppressing JNK signaling pathways. | 2017 | Details |
| A14770 | 29247558 | Diabet Med | European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. | 2018 | Details |
| A14771 | 29247356 | J Gastroenterol | Current and future pharmacological therapies for NAFLD/NASH. | 2017 | Details |